A5025486281- Malaria Research and Control
- Mosquito-borne diseases and control
- Food Allergy and Anaphylaxis Research
- Mast cells and histamine
- Complement system in diseases
- HIV Research and Treatment
- Allergic Rhinitis and Sensitization
- Polyamine Metabolism and Applications
- Hepatitis B Virus Studies
- Immune Cell Function and Interaction
- Immune Response and Inflammation
- Invertebrate Immune Response Mechanisms
- Antimicrobial Peptides and Activities
- Viral Infectious Diseases and Gene Expression in Insects
- Glycosylation and Glycoproteins Research
- vaccines and immunoinformatics approaches
- Advanced Drug Delivery Systems
- Influenza Virus Research Studies
- Viral Infections and Vectors
- Hepatitis C virus research
- RNA Interference and Gene Delivery
- Viral Infections and Immunology Research
- NF-κB Signaling Pathways
- Immunotherapy and Immune Responses
- Drug Transport and Resistance Mechanisms
Novavax (Sweden)
2014-2025
Novavax (United States)
2021-2023
Kungälvs Sjukhus
2023
Jenner Institute
2022
Oxford BioMedica (United Kingdom)
2022
University of Oxford
2022
Serum Institute of India (India)
2022
Institut de Recherche en Sciences de la Santé
2022
Uppsala University
2005-2012
Saponin-based adjuvants are widely used to enhance humoral and cellular immune responses towards vaccine antigens, although it is not yet completely known how they mediate their stimulatory effects. The aim of this study was elucidate the mechanism action adjuvant Matrix-M™ without antigen Alum as reference adjuvant. Adjuvant comprised 40 nm nanoparticles composed Quillaja saponins, cholesterol phospholipid. BALB/c mice were subcutaneously injected once with, 3, 12 or 30 µg Matrix-M™,...
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a clinical trials to assess targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well a adjuvant formulation (PvDBPII/Matrix-M) were tested in both standard delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside...
BACKGROUNDMalaria transmission-blocking vaccines aim to interrupt the transmission of malaria from one person another.METHODSThe candidates R0.6C and ProC6C share 6C domain Plasmodium falciparum sexual-stage antigen Pfs48/45. utilizes glutamate-rich protein (GLURP) as a carrier, includes second (Pfs230-Pro) short 36-amino acid circumsporozoite (CSP) sequence. Healthy adults (n = 125) malaria-endemic area Burkina Faso were immunized with 3 intramuscular injections, 4 weeks apart, 30 μg or 100...
Abstract The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds antigen on reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed dosing regimen with recombinant PvDBPII SalI variant formulated adjuvant Matrix-M TM reduced in vivo parasite multiplication rate (PMR) immunized volunteers challenged Thai P. isolate PvW1. Here, we describe extensive analysis polyfunctional antibody responses...
SummaryBackgroundMalaria remains a substantial public health burden among young children in sub-Saharan Africa and highly efficacious vaccine eliciting durable immune response would be useful tool for controlling malaria. R21 is malaria comprising nanoparticles, formed from circumsporozoite protein hepatitis B surface antigen (HBsAg) fusion protein, without any unfused HBsAg, administered with the saponin-based Matrix-M adjuvant. This study aimed to assess safety immunogenicity of candidate,...
The cysteine-rich Pfs48/45 protein, a Plasmodium falciparum sexual stage surface has been advancing as candidate antigen for transmission-blocking vaccine (TBV) malaria. However, contains multiple disulfide bonds, that are critical proper folding and induction of (TB) antibodies. We have previously shown R0.6C, fusion the 6C domain fragment PfGLURP (R0), expressed in Lactococcus lactis, was properly folded induced Here we describe process development technology transfer scalable reproducible...
Abstract The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that Pfs230–Pfs48/45 fusion protein elicits higher levels of functional antibodies than the individual antigens, but low yields hampered progression to clinical evaluation. Here identified modified construct (ProC6C) with circumsporozoite (CSP) repeat-linker sequence enhances expression. A scalable reproducible process in Lactococcus...
ABSTRACT Background Improvements in malaria control have stalled recently and new tools are needed. The R21 vaccine is comprised of the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg). It forms particles that lack excess HBsAg frequently tested candidate, RTS,S/AS01 . Methods We conducted an open-label, first-in-human, Phase Ia study evaluating safety immunogenicity administered alone with saponin-based adjuvant, Matrix-M ™ (MM). Twenty-eight healthy adults received...
Background: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, most vaccine candidate to date, demonstrated 55·8% (97·5% confidence interval [CI], 51-60) efficacy over 12 months African children.Methods: We conducted a double-blind, randomised, controlled trial of low-dose circumsporozoite protein-based vaccine, R21, with two different doses adjuvant, Matrix-M™ (MM), children aged 5-17 Nanoro, Burkina Faso,...
Background: Basophils are inflammatory cells associated with allergy and parasite infections. Investigation of their true biological function has long been hampered by the difficulty in obtaining sufficient amounts pure basophils lack phenotypic markers. Moreover, it very difficult to clone identify basophil‐specific granule proteins, partially because an almost complete mRNA mature circulating basophils. Methods: To obtain transcriptionally active immature basophils, umbilical cord blood...
Basophils are blood cells of low abundance associated with allergy, inflammation and parasite infections. To study the transcriptome mature circulating basophils were purified from buffy coats by density gradient centrifugations two-step magnetic cell sorting. However, after extensive analysis found to be transcriptionally inactive almost completely lack functional mRNA. In order obtain active immature for their transcriptome, umbilical cord therefore cultured in presence interleukin (IL)-3...
There are no licensed vaccines against Plasmodium vivax , the most common cause of malaria outside Africa.We conducted two Phase I/IIa clinical trials to assess safety, immunogenicity and efficacy targeting region II P. Duffy-binding protein (PvDBPII). Recombinant viral (using ChAd63 MVA vectors) were administered at 0, 2 months or in a delayed dosing regimen (0, 17, 19 months), whilst protein/adjuvant formulation (PvDBPII/Matrix-M™) was monthly 1, months) 14 months). Delayed regimens due...
Abstract The invasion of reticulocytes by Plasmodium vivax merozoites is dependent on the interaction Duffy Binding Protein (PvDBP) with antigen receptor for chemokines (DARC). N-terminal cysteine-rich region II PvDBP (PvDBPII), which binds DARC, a leading P. malaria vaccine candidate. Here, we have evaluated immunogenicity recombinant PvDBPII formulated adjuvants Matrix-M and GLA-SE in mice. Analysis antibody responses revealed comparable ELISA recognition titres as well similar native...
Abstract The receptor-binding domain, region II, of Plasmodium vivax Duffy binding protein (PvDBPII) binds the antigen on reticulocytes to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed dosing regimen with recombinant PvDBPII SalI formulated adjuvant Matrix-M TM reduced in vivo parasite multiplication rate (PMR) challenged P. Thai isolate PvW1. We describe extensive analysis polyfunctional antibody responses elicited by immunization and identify...
<h3>Background</h3> Malaria transmission blocking vaccines (TBV) hold the potential to block malaria in population thereby contributing elimination by producing specific antibodies against functionally important proteins expressed during parasite development mosquito. The Plasmodium falciparum Pfs230 and Pfs48/45 are leading candidates for a TBV, while Circumsporozoite Protein (CSP) remains candidate an anti-infection Vaccine. <h3>Methods</h3> A scalable reproducible product process...